Topical Steroid Withdrawal — What Your Patients Are Watching Online Topical steroid withdrawal (TSW) is an increasingly visible — and misunderstood — drug‑related dermatosis that can follow abrupt discontinuation of…
Rethinking AD — Beyond Inflammation Atopic dermatitis remains common and stubborn, especially in pediatric patients, because inflammation is only one part of a self‑reinforcing loop that includes microbiome disruption, neuroimmune…
Meet Dr. Theodore (Ted) J. Daly Theodore (Ted) J. Daly MD has been in private practice at Garden City Dermatology, New York, for nearly four decades. He received his medical…
Microdosed Actives Target Dermal Senescence - A Surprising Lab Advance That Could Reshape Dermatoporosis Care Dermatoporosis —age‑related thinning and fragility of the skin driven by fibroblast dysfunction, ECM breakdown, and…
Influenza Vaccination and Arm Nodules: Uncovering a Hidden Risk A large propensity-matched cohort study using TriNetX data found that intramuscular influenza vaccination carries a 32% higher risk of developing subcutaneous…
Sunscreen ... our daily epi/dermal defense, our solar safeguard, our broad-spectrum BFF for life. Yet lurking in the shaded areas are unfounded fears: “Sunscreen causes cancer; Sunscreen is an endocrine…
Dermatology On-Call Data Uncover Trends in Hematology–Oncology Cutaneous Complications Oncodermatology consults for hematological malignancy patients often uncover therapy-related skin toxicities that can derail cancer treatment. In a retrospective review of…
Curated by the JDD Editors Missed any of our October highlights? October is our Atopic Dermatitis focused issue–start to dive in! Catch up with this curated roundup from the JDD…
Test Your Knowledge! Join Dr. Alexis Carrington, Chief Dermatology Resident at George Washington University, to help understand dermatologic conditions across all skin tones. Decoding Derm: What’s the Diagnosis is a…
Check Out JDD Corner's Latest Author Spotlight Our current Author Spotlight features Omar Ibrahimi MD PhD and Catherine Di Giorgio MD, two of the co-authors who ran the clinical trials for…
Fast itch relief and comparable skin clearance at week 4 - a nonsteroidal option to note for mild-moderate AD In a phase 2, dose‑ranging trial, twice‑daily 1.5% ruxolitinib cream matched…
A simple 1% colloidal oatmeal regimen cut itch and improved eczema scores within days in toddlers A small open‑label study in children aged 3-72 months tested a twice‑daily 1% colloidal…